吉西他滨联合化疗与其他方案治疗晚期非小细胞肺癌233例疗效比较.PDFVIP

海南医学2014年1月第25卷第1期 Hainan Med J, Jan. 2014, Vol. 25, No. 1 doi:10.3969/j.issn.1003-6350.2014.01.0006 ·论 著· 吉西他滨联合化疗 与其他方案治疗晚期非小细胞肺癌233例疗效比较 林立平，胡家柱，黄福喜，李微绽，黎秀月，韩建军，曹小龙 (广州市番禺区中心医院肿瘤科，广东 广州 511400) 【摘要】 目的 观察吉西他滨联合化疗与其他方案治疗晚期非小细胞肺癌(NSCLC)的疗效。方法 233 例 晚期NSCLC 按照一线所接受化疗方案分为吉西他滨联合化疗组与其他方案组，按照实体瘤疗效评价标准 (RECIST)进行疗效评价。结果 118例患者接受吉西他滨联合化疗，另外115例接受其他方案化疗。吉西他滨 联合化疗组与其他方案组客观有效率(42.4% vs 42.6%)、疾病稳定(31.4% vs 27.8%)、疾病进展(26.3% vs 29.6%)情 况差异无统计学意义(P=0.790) ，两组中位生存时间(MST)分别为18.1个月和14.3个月(P=0.010) ，中位无进展生 存(PFS)为5.9 个月和5.7 个月(P=0.987) 。结论 吉西他滨联合化疗与其他方案方案治疗晚期NSCLC 近期疗效 和PFS 相似，但吉西他滨联合化疗的总生存时间较长。 【关键词】 晚期非小细胞肺癌；吉西他滨；化疗 【中图分类号】R734.2 【文献标识码】A 【文章编号】 1003—6350（2014 ）01—0018—04 Comparisonofgemcitabinecombinedwithchemotherapyandotherregimensinthetreatmentofadvanced non-smallcelllungcancer.LINLi-ping,HUJia-zhu,HUANGFu-xi,LIWei-zhan,LIXiu-yue,HANJian-jun,CAO Xiao-long.DepartmentofOncology,CentralHospitalofPanyu，Guangzhou511400,Guangdong,CHINA 【Abstract】 Objective To observe the efficacy of gemcitabine with combined chemotherapy and other regimens in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 233 patients with advanced NSCLC were divided into gemcitabine combined with chemotherapy group and other regimens group according to the first line chemotherapy. The response evaluation criterion in solid tumor (RECIST) was used to evaluate the response. Results 118 patients accepted gemcitabine combined with chemotherapy and 115 patients accepted other regimens. There were no significant difference in objective response rate (42.4% vs 42.6%), stable disease (31.4% vs 27.8%) and pr